Apolipoprotein E Polymorphism and Brain Morphology in Mild Cognitive Impairment

Background: The apolipoprotein E (ApoE) genotype has been confirmed as the major genetic risk factor for late-onset Alzheimer’s disease (AD). How the ApoE genotype and brain morphology relate to each other is only partly understood, particularly in mild cognitive impairment, the assumed prestage of AD. Methods: A total of 83 subjects with mild cognitive impairment (aging-associated cognitive decline criteria) were investigated with optimized voxel-based morphometry (VBM). We tested for differences in gray and white matter densities between groups according to their ApoE status, i.e. Ε4 allele noncarriers (n = 42), subjects with one Ε4 allele (n = 27) and subjects with two Ε4 alleles (n = 14). Results: In individuals carrying two Ε4 alleles, VBM revealed a decline in gray matter density predominantly in the medial temporal lobe region. Subjects with a single copy of the Ε4 allele exhibited gray matter atrophy in the right inferior frontal gyrus. With respect to white matter changes, atrophy was only found in subjects homozygous for Ε4 and confined to the right superior and middle temporal gyrus. Conclusion: Our findings support the hypothesis that the ApoE genotype in mild cognitive impairment might be associated with structural changes typically found in the early stages of AD.

[1]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[2]  A D Roses,et al.  Apolipoprotein E and Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Karl J. Friston,et al.  A Voxel-Based Morphometric Study of Ageing in 465 Normal Adult Human Brains , 2001, NeuroImage.

[4]  R. Lévy,et al.  Aging-Associated Cognitive Decline , 1994, International Psychogeriatrics.

[5]  John J Sidtis,et al.  Abnormal white matter integrity in healthy apolipoprotein E epsilon4 carriers , 2005, Neuroreport.

[6]  Charles DeCarli,et al.  Sex, Apolipoprotein E ε4 Status, and Hippocampal Volume in Mild Cognitive Impairment , 2005 .

[7]  G. Schmitz,et al.  High-speed apolipoprotein E genotyping and apolipoprotein B3500 mutation detection using real-time fluorescence PCR and melting curves. , 1999, Clinical chemistry.

[8]  Pei-Ning Wang,et al.  The MCI study in Taiwan. , 2006, Acta neurologica Taiwanica.

[9]  H C Charles,et al.  Impact of APOE in mild cognitive impairment , 2004, Neurology.

[10]  J. Wesson Ashford,et al.  ApoE genotype accounts for the vast majority of AD risk and AD pathology , 2004, Neurobiology of Aging.

[11]  Daniel Bandy,et al.  Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. , 2007, The American journal of psychiatry.

[12]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[13]  Jim Mintz,et al.  Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia. , 2006, Archives of general psychiatry.

[14]  L Nyberg,et al.  Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD? , 2006, Neurology.

[15]  Charles DeCarli,et al.  Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. , 2005, Archives of neurology.

[16]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[17]  Andrew J. Saykin,et al.  Regional brain atrophy in cognitively intact adults with a single APOE ε4 allele , 2006, Neurology.

[18]  R J Havel,et al.  Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. , 1982, Journal of lipid research.

[19]  Richard J. Caselli,et al.  Correlations Between Apolipoprotein E ε4 Gene Dose and Whole Brain Atrophy Rates , 2007 .

[20]  Yadong Huang Apolipoprotein E and Alzheimer disease , 2006, Neurology.

[21]  Peter Schönknecht,et al.  Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young-old subjects. , 2005, The American journal of psychiatry.

[22]  G J Tsongalis,et al.  Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. , 2006, Neurology.

[23]  R Levy,et al.  Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. , 1994, International psychogeriatrics.

[24]  Nicolas Cherbuin,et al.  Neuroimaging and APOE Genotype: A Systematic Qualitative Review , 2007, Dementia and Geriatric Cognitive Disorders.

[25]  H. Soininen,et al.  Apolipoprotein E ε4 Allele Is Associated with Increased Atrophy in Progressive Mild Cognitive Impairment: A Voxel-Based Morphometric Study , 2008, Neurodegenerative Diseases.

[26]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[27]  L Nyberg,et al.  Altered brain white matter integrity in healthy carriers of the APOE ε4 allele , 2006, Neurology.

[28]  Karen Ritchie,et al.  Classification criteria for mild cognitive impairment: A population-based validation study , 2001 .

[29]  Marina Boccardi,et al.  The Effect of Apolipoprotein Polymorphism on Brain in Mild Cognitive Impairment: A Voxel-Based Morphometric Study , 2006, Dementia and Geriatric Cognitive Disorders.

[30]  Karl J. Friston,et al.  Voxel-Based Morphometry—The Methods , 2000, NeuroImage.

[31]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.